<DOC>
	<DOCNO>NCT02268760</DOCNO>
	<brief_summary>To assess safety , tolerance pharmacokinetics 5 mg 2400 mg BILN 2061 ZW 1 . In rise single dos 2 . With without 64 g fat breakfast one select dose</brief_summary>
	<brief_title>Safety , Tolerance , Pharmacokinetics BILN 2061 ZW Healthy Male Subjects , Combined With Preliminary Evaluation Food Effect</brief_title>
	<detailed_description />
	<criteria>Healthy male subject determine result screen Signed write informed consent accordance good clinical practice ( GCP ) local legislation Age ≥ 18 ≤ 50 year Broca ≥ 20 % ≤ + 20 % Any finding medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance History current gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunologic , hormonal disorder , include history viral hepatitis , serological evidence active Hepatitis B Hepatitis C infection History orthostatic hypotension , faint spell blackouts Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within 1 month prior administration Use drug might influence result trial within 10 day prior administration trial Participation another trial investigational drug within 1 month prior administration trial Smoker ( &gt; 10 cigarette 3 cigar 3 pipes/day ) inability refrain smoke trial day Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood donation within 1 month prior administration trial Excessive physical activity within 5 day prior administration trial Any laboratory value outside clinically accept reference range clinical relevance History familial bleeding disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>